Clown-Free Zone... sorry, no clowns allowed Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lucretius who started this subject	2/20/2004 2:31:55 PM
From: clutterer	of 436258

anybody watching BSX over here? Boston Scientific Could See Earnings Surge Forbes.com staff, 02.17.04, 11:07 AM ET Tear Sheet \| Chart \| News NEW YORK - J.P. Morgan said earnings growth for Boston Scientific (nyse: BSX - news - people ) from 2004-2005 "should be unlike any before in medical device history." J.P. Morgan's forecast calls for earnings per share climbing from 62 cents in 2003 to $1.65 in 2004 and $2.35 in 2005. The research firm expects Boston Scientific, which focuses on less-invasive, catheter-based therapeutics, to capture 65% to 70% of the drug-eluting stent market in 2004-2005. J.P. Morgan, which rates Boston Scientific at "overweight," said the company's Feb. 23 analyst meeting is "arguably the big event for Boston's stock in 2004, right behind the launch of Taxus," a drug-coated stent. "Should management effectively sell the Street on its 2006 outlook, including its ability to effectively put to use its substantial Taxus generated free cash flow, multiple expansion could ensue," J.P. Morgan said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next